Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

IDH-mutant glioma

Trial arms side by side.

One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.

ClassNone selected

No arms selected. Choose a drug, an arm, or a preset.

Each arm uses its closest stored timepoint inside the window.

Cross-trial values

value

Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.

No selected arm has this endpoint inside the time window.

Show as table
ArmTrialPhasePopulationnComparatorTimepointEstimandAssessorValue

Not shown

Every selected arm is drawn.

7 of 9 arms with a reported figure. Choose arms to narrow the chart.

Drug, trialPopulationDoseEstimandComparatorORR, %mPFS, monthsmOS, monthsHazard ratioOther
Vorasidenib 40 mgINDIGOgrade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery only (n = 168 vs 163)40 mgITTplaceboobjective response rate, extended follow-up: 20.8%, ASCO 2026, preliminarymedian PFS, vorasidenib: 27.7 months, NEJM 2023median PFS, placebo: 11.1 months, NEJM 2023median PFS, extended follow-up: 44.1 months, ASCO 2026, preliminaryn/rPFS hazard ratio vs placebo (BIRC): 0.39 HR, primary analysistime to next intervention hazard ratio: 0.26 HR, primary analysismedian time to next intervention, placebo: 17.8 months, primary analysis
Vorasidenib Phase 1 dosesVorasidenib Phase 1recurrent non-enhancing IDH-mutant glioma (n = 22)Phase 1 dosesSingle armn/robjective response rate: 18%, Phase 1median PFS: 36.8 months, Phase 1n/rn/rn/r
Safusidenib (AB-218, DS-1001) 250 mgJ201 Phase 2IDH1-mutant grade 2 glioma, Japan (n = 27 per company; registry n = 25)250 mgSingle armn/rconfirmed objective response rate: 51.9%, median follow-up 38.8 months36-month PFS rate: 79.1%, median follow-up 38.8 monthsn/rn/rn/r
Olutasidenib 150 mgOlutasidenib Phase 1/2 (glioma cohort)relapsed or refractory IDH1-mutant glioma (26 enrolled, 25 evaluable)150 mgSingle armn/robjective response rate: 8%, 2 of 25n/rn/rn/rdisease control rate: 48%, 12 of 25
Ivosidenib Phase 1 dosesIvosidenib Phase 1 (glioma)recurrent non-enhancing IDH1-mutant gliomaPhase 1 dosesSingle armn/rn/rmedian PFS: 13.6 months, 95% CI 9.2 to 33.2n/rn/rn/r
IDH1-VAC (IDH1 R132H Peptide Vaccine) not stated in sourceNOA-16newly diagnosed IDH1 R132H astrocytomanot stated in sourceSingle armn/rn/r3-year PFS rate: 63%n/rn/rvaccine-induced immune response: 93.3%, 28 of 30 evaluable
Olaparib 300 mgOLAGLIrecurrent IDH-mutant high-grade glioma (n = 35)300 mgSingle armn/rn/r6-month PFS rate: 31.4%, primary endpoint, target 50% not metmedian PFS: 2.05 monthsmedian OS: 15.9 monthsn/rn/r

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.